title: [Vincristine treatment for management of alarming hemangiomas in infancy].
abstract: Hemangioma is the most benign vascular tumor encountered in infancy; its incidence is 10-12% at 1 year of age. It usually appears a few weeks after birth, and rather rapidly grows until the age of 10-12 months; it then stabilizes and spontaneously regresses towards a complete disappearance over 5 - 10 years. Therefore, most hemangiomas need no treatment, but just a close clinical follow up. However, some hemangiomas (10-20% of cases), because of their location and/or complications, can have very serious aesthetic, functional, or even vital consequences: these require a more aggressive approach. A pharmacologic initial therapy based on high doses of corticosteroids or interferon alpha 2a or 2b has gained wide acceptance, but can entail serious side-effects. Vincristine represents a safe and effective treatment option for the management of those alarming hemangiomas.
authors.affiliation: Hémato-Oncologie pédiatrique, CHR Citadelle, Liège, Belgique. claire.hoyoux@chrcitadelle.be
authors.forename: C
authors.initials: C
authors.lastname: Hoyoux
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D012878:Skin Neoplasms / Q000188:drug therapy; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine